

18
C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

GLENN et al.

Appln. No. 09/257,188

Filed: February 25, 1999



Atty. Ref.: 4057-32

Group Art Unit: 1644

Examiner: G. Ewoldt

FOR: USE OF PENETRATION ENHancers AND BARRIER DISRUPTION AGENTS
TO ENHANCE THE TRANScUTANEOUS IMMUNE RESPONSE

* * *

AMENDMENT UNDER 37 CFR § 1.111

December 31, 2001

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

In reply to the pending Office Action (Paper No. 15) of October 9, 2001, entry and consideration of the following amendments and remarks are respectfully requested

IN THE TITLE

Kindly replace the present title with the following: USE OF PENETRATION ENHancers AND BARRIER DISRUPTION AGENTS TO ENHANCE THE TRANScUTANEOUS IMMUNE RESPONSE

IN THE SPECIFICATION

Kindly enter the following amended paragraphs.

Page 50, delete the third paragraph starting on line 24 and replace it with the following:

Co-administration of DT and a control DNA sequence (SEQ ID NO:1; CpG2, TCCAAATGAGCTTCCTGAGTCT) failed to induce a detectable rise in the anti-DT titers. In contrast, addition of a DNA sequence containing an unmethylated CpG dinucleotide flanked by two 5' purines and two 3' pyrimidines (SEQ ID NO:2; immunostimulatory CpG1: TCCATGACGTTCTGACGTT) resulted in a detectable increase in the serum